Fatal Fungal Infection Has Unique Growth Patterns
|
By LabMedica International staff writers Posted on 08 Sep 2016 |

Image: A microscopic appearance of non-aggregate-forming isolates (A) and aggregate-forming isolates (B) of Candida auris in phosphate buffered saline suspensions (Photo courtesy of Public Health England).
The multidrug-resistant yeast Candida auris, which has caused fatal infections in some hospitalized patients, has at least two different growth patterns and some of its strains are as capable of causing disease as the most invasive type of yeast called Candida albicans.
Normally, a yeast copies itself and divides during growth, but the C. auris samples differ in their growth characteristics in the laboratory, with a proportion failing to separate after budding, resulting in the formation of large clumps of cells that could not be physically disrupted.
Mycology specialists at the Public Health England Mycology Reference Laboratory (Bristol, UK) characterized 12 C. auris isolates by ribosomal DNA (rDNA) gene sequencing targeting the 28S rRNA or by internal transcribed spacer 1 (ITS1) regions and matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) analysis or by a combination of the two methods.
The scientists compared the pathogenicity, or disease-causing potential, of the C. auris samples taken from patients treated at six National Health Service hospitals in England with samples of other disease-causing Candida species. To do so, they injected young wax moth larvae (called Galleria mellonella, an insect model used to study human infection) with the assorted Candida samples to measure progression of disease. The investigators also found strain-specific differences in the behavior of C. auris, with the clumped strains being less capable of causing disease than the ones that did not clump. The strains that did not clump were as capable of causing disease as another type of Candida called C. albicans, which is currently believed to have the most disease-causing potential in the Candida family.
Elizabeth Johnson, PhD, director of the National Mycology Reference Laboratory and co-author of the study, said, “Despite receiving considerable attention since its first description, little is known concerning the disease-causing potential of this emerging fungal pathogen. We were surprised to find two very different growth forms of C. auris depending on the strain. We were also surprised by the virulence of this species because in most other types of Candida, the ability to cause disease relates to the organism's ability to form hyphae (fine, branching tube-like structures). C. auris is not able to form these hyphae in the laboratory or in the insect infection model, so we would have predicted reduced ability to cause disease.” The study was published on August 18, 2016, in the journal mSphere.
Related Links:
Public Health England Mycology Reference Laboratory
Normally, a yeast copies itself and divides during growth, but the C. auris samples differ in their growth characteristics in the laboratory, with a proportion failing to separate after budding, resulting in the formation of large clumps of cells that could not be physically disrupted.
Mycology specialists at the Public Health England Mycology Reference Laboratory (Bristol, UK) characterized 12 C. auris isolates by ribosomal DNA (rDNA) gene sequencing targeting the 28S rRNA or by internal transcribed spacer 1 (ITS1) regions and matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) analysis or by a combination of the two methods.
The scientists compared the pathogenicity, or disease-causing potential, of the C. auris samples taken from patients treated at six National Health Service hospitals in England with samples of other disease-causing Candida species. To do so, they injected young wax moth larvae (called Galleria mellonella, an insect model used to study human infection) with the assorted Candida samples to measure progression of disease. The investigators also found strain-specific differences in the behavior of C. auris, with the clumped strains being less capable of causing disease than the ones that did not clump. The strains that did not clump were as capable of causing disease as another type of Candida called C. albicans, which is currently believed to have the most disease-causing potential in the Candida family.
Elizabeth Johnson, PhD, director of the National Mycology Reference Laboratory and co-author of the study, said, “Despite receiving considerable attention since its first description, little is known concerning the disease-causing potential of this emerging fungal pathogen. We were surprised to find two very different growth forms of C. auris depending on the strain. We were also surprised by the virulence of this species because in most other types of Candida, the ability to cause disease relates to the organism's ability to form hyphae (fine, branching tube-like structures). C. auris is not able to form these hyphae in the laboratory or in the insect infection model, so we would have predicted reduced ability to cause disease.” The study was published on August 18, 2016, in the journal mSphere.
Related Links:
Public Health England Mycology Reference Laboratory
Latest Microbiology News
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
- Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
- Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Channels
Clinical Chemistry
view channel
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read moreMolecular Diagnostics
view channel
Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease
Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more
Genomic Test Guides Extended Endocrine Therapy in Early Breast Cancer
Adjuvant endocrine therapy is standard for hormone receptor–positive early breast cancer, yet prolonged treatment brings side effects and adherence problems. Whether to continue beyond five years is a... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read morePathology
view channel
Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
Bleeding after menopause requires prompt investigation for uterine cancer, although most women who undergo testing do not have the disease. In the U.K., uterine cancer affects nearly 10,000 women each... Read more
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read moreTechnology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







